What was approved is a once daily version of their best selling drug Xibrom (<70 % of profits/ and revenues). ISTA was in trouble because Xibrom had its patent expire in 2009, and there were generic makers who began filing with the FDA. This decision will give them atleast 3 more years onto the patent (according to the company). This means that it helps to lock in their substantial source of revenue for atleast three more years, and also forces Generic drug makers to I believe start all over again. Hope this helps GLTA.